Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | AOC2 | O75106 | 6/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16767549 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9AOC2 | |
| SCHEMBL24295299 | 0.87 | CA1 (0.63) | CA12CA1CA2CA9AOC2 | |
| SCHEMBL23852233 | 0.87 | CA1 (0.63) | CA12CA1CA2CA9AOC2 | |
| SCHEMBL15527849 | 0.85 | ALDH1A1 (0.47) | AOC2MAOBRAB9AALDH1A1PTPN1 | |
| SCHEMBL15527848 | 0.85 | ALDH1A1 (0.47) | AOC2MAOBRAB9AALDH1A1PTPN1 | |
| SCHEMBL23370042 | 0.85 | MAOB (0.64) | CA12CA1CA2CA9AOC2 | |
| SCHEMBL24906961 | 0.83 | AOC2 (0.67) | CA12CA1CA2CA9AOC2 | |
| SCHEMBL16766885 | 0.83 | AOC2 (0.46) | AOC2MAOBRAB9AALDH1A1PTPN1 | |
| SCHEMBL23329639 | 0.83 | MAOB (0.46) | CA12CA1CA2CA9AOC2 | |
| SCHEMBL16767233 | 0.83 | MAOB (0.47) | CA12CA1CA2CA9AOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-03-07 | — | — | US | disclosed |
| EP-3438087-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438087-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-10160723-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-25 | — | — | US | disclosed |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| EP-2844637-B1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2844637-B1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9815782-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815782-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | AOC3, HAO1, VAPA | CA12 4182/4885CA1 4596/4885CA2 3059/4885 |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | AOC3, HAO1, VAPA | CA12 4182/4885CA1 4596/4885CA2 3059/4885 |
| US-10160723-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | AOC3, HAO1, VAPA | CA12 4182/4885CA1 4596/4885CA2 3059/4885 |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | AOC3, HAO1, VAPA | CA12 4182/4885CA1 4596/4885CA2 3059/4885 |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | HAO1, VAPA, AOC3 | CA12 4435/4885CA1 4634/4885CA2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.